Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2022-05-26 Board/Management Inform…
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
公告本公司財務、會計主管及治理主管異動
Board/Management Information Classification · 100% confidence The document is a short announcement (745 characters) about changes in key company personnel, specifically the financial, accounting, and governance officers. It details the outgoing and incoming persons, their titles, and the effective date of the change. There is no financial data, report, or presentation content. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document is not a report or a regulatory filing but a direct announcement of management changes.
2022-05-26 Chinese
公告本公司透明質酸三針劑型直鏈關節腔注射劑 Flexotron Plus(2%)產品取得銷售許可證書。
Regulatory Filings Classification · 95% confidence The document is a short announcement (830 characters) from a company (科妍生物科技股份有限公司) about obtaining a sales permit for a medical product (透明質酸三針劑型直鏈關節腔注射劑 Flexotron Plus(2%)). It includes details about the product, regulatory approval, and market implications. There is no financial data, no mention of a report being attached or published, and no indication of a meeting or voting results. The content is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it does not match any other specific category such as financial reports, management changes, or capital updates.
2022-05-26 Chinese
111年第1季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure related to investment in overseas subsidiaries, showing investment amounts, holding percentages, and recognized investment gains or losses for a specific quarter (111年1季, which corresponds to Q1 of the 111th year in the Taiwanese calendar). The content is concise and tabular, focusing on investment details rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). The document length is only 662 characters, indicating it is a short disclosure rather than a full report. This type of document aligns best with a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2022-05-12 Chinese
111年第1季大陸投資
Regulatory Filings Classification · 90% confidence The document is a detailed tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes specific financial figures, investment methods, and regulatory limits, along with explanatory notes referencing accounting practices and regulatory bodies such as the Ministry of Economic Affairs Investment Commission. The document length is 1286 characters, which is relatively short but contains substantive financial data rather than just an announcement or a certification. It is not a full annual or interim report, nor is it a simple announcement or certification. The content aligns with a regulatory filing providing detailed investment information as required by regulatory authorities. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-05-12 Chinese
111年第1季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated statement of changes in equity for a company, with detailed financial figures for the first quarter of the year 111 (Taiwan calendar) and the previous year's first quarter. The data includes equity components such as common stock, capital surplus, legal reserve, special reserve, undistributed earnings, retained earnings, foreign currency translation adjustments, and total equity. The presence of quarterly financial data and the detailed breakdown of equity changes indicate this is a financial report for a period shorter than a full fiscal year. The document length is 2764 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-05-12 Chinese
111年第1季現金流量表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated cash flow statement for the first quarter of the fiscal year 111 (which corresponds to 2022 in the Gregorian calendar). It includes detailed financial data such as net profit before tax, depreciation, amortization, interest expenses and income, changes in working capital, and cash flows from operating, investing, and financing activities. The presence of actual financial figures and the quarterly period covered indicate this is a comprehensive interim financial report. The document length is 2079 characters, which is relatively short but contains substantive financial data, so it is not merely an announcement or certification. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2022
2022-05-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.